Stapled peptides — chemically reinforced to hold their 3D shape — are emerging as more stable, cell-penetrating alternatives to conventional peptide drugs for treating diabetes and metabolic disorders.
3 functional modesStapled peptides can act as agonists, antagonists, or dual-agonists by disrupting protein-protein interactions — offering versatile therapeutic approaches for metabolic disease.
What the researchers found
Stapled peptides represent a significant advancement in peptide drug design for metabolic diseases. By stabilizing the α-helical conformation through chemical cross-links, these peptides gain enhanced stability against enzymatic degradation, improved cellular permeability, and stronger binding affinity for their targets.
The review describes how stapled peptides can function as agonists, antagonists, or dual-agonists by disrupting specific protein-protein interactions in metabolic pathways. Key targets include molecular pathways involved in glucose metabolism, insulin secretion, and food intake regulation. However, challenges remain in optimizing structural stability, controlling peptide helicity, managing isomer mixtures during synthesis, and minimizing potential side effects.
Why it matters
Peptide therapeutics are one of the fastest-growing drug classes, but their clinical potential is limited by poor stability and inability to reach intracellular targets. Stapling technology directly addresses these fundamental limitations. If stapled peptides can be reliably manufactured and prove safe in clinical trials, they could unlock an entirely new category of metabolic disease treatments targeting protein-protein interactions that are currently considered 'undruggable' by conventional peptide approaches.
How the study worked
This is a comprehensive narrative review that surveys the published literature on stapled peptide technology and its application to diabetes and metabolic diseases. The review covers stapling chemistry, structural considerations, target pathways, and development challenges.
What this study cannot tell us
As a review article, this work synthesizes existing research rather than presenting new experimental data. Most stapled peptides for metabolic disease are still in preclinical stages, and the review acknowledges significant challenges including manufacturing complexity (isomer control), achieving consistent helicity, and limited clinical safety data. The jump from promising in vitro properties to effective in vivo therapeutics remains unproven for most metabolic stapled peptides.
How to read the evidence
This is a comprehensive review article summarizing the current state of stapled peptide technology for metabolic diseases. It synthesizes preclinical and early-stage research but does not present new clinical data. The evidence for stapled peptides in metabolic disease is largely preclinical.
When this study was published
Published in 2024, this is a very current review capturing the latest developments in stapled peptide technology. The field is evolving rapidly, with new stapled peptide candidates entering preclinical pipelines.
The bigger picture
Peptide stapling is part of a broader trend in drug development toward 'beyond rule-of-five' therapeutics — molecules that bridge the gap between small-molecule drugs and biologics. While the first stapled peptide to reach clinical trials targeted cancer (ALRN-6924), the technology is now expanding into metabolic disease. Given the enormous commercial success of GLP-1 receptor agonists, applying stapling technology to next-generation metabolic peptide drugs could yield therapeutics with oral bioavailability, longer half-lives, and access to intracellular targets.
Questions still open
- Can stapled peptide technology enable oral delivery of GLP-1 or other metabolic peptide drugs, eliminating the need for injections?
- Which specific protein-protein interactions in metabolic pathways are most amenable to disruption by stapled peptides?
- How will the manufacturing and cost challenges of stapled peptide synthesis be addressed for large-scale production?
Common questions
What does it mean to 'staple' a peptide?
Could stapled peptides replace current diabetes injections like semaglutide?
Read the original research
Stapled peptides as potential therapeutics for diabetes and other metabolic diseases.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 180, 117496
Citation
Nielipińska, Dominika; Rubiak, Dominika; Pietrzyk-Brzezińska, Agnieszka J; Małolepsza, Joanna; Błażewska, Katarzyna M; Gendaszewska-Darmach, Edyta. (2024). Stapled peptides as potential therapeutics for diabetes and other metabolic diseases.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 180, 117496. https://doi.org/10.1016/j.biopha.2024.117496